The Gut-Heart Axis: Updated Review for The Roles of Microbiome in Cardiovascular Health
- Author:
Thi Van Anh BUI
1
;
Hyesoo HWANGBO
;
Yimin LAI
;
Seok Beom HONG
;
Yeon-Jik CHOI
;
Hun-Jun PARK
;
Kiwon BAN
Author Information
- Publication Type:State of the Art Review
- From:Korean Circulation Journal 2023;53(8):499-518
- CountryRepublic of Korea
- Language:English
- Abstract: Cardiovascular diseases (CVDs), including coronary artery disease, stroke, heart failure, and hypertension, are the global leading causes of death, accounting for more than 30% of deaths worldwide. Although the risk factors of CVDs have been well understood and various treatment and preventive measures have been established, the mortality rate and the financial burden of CVDs are expected to grow exponentially over time due to the changes in lifestyles and increasing life expectancies of the present generation. Recent advancements in metagenomics and metabolomics analysis have identified gut microbiome and its associated metabolites as potential risk factors for CVDs, suggesting the possibility of developing more effective novel therapeutic strategies against CVD. In addition, increasing evidence has demonstrated the alterations in the ratio of Firmicutes to Bacteroidetes and the imbalance of microbial-dependent metabolites, including short-chain fatty acids and trimethylamine N-oxide, play a crucial role in the pathogenesis of CVD. However, the exact mechanism of action remains undefined to this day. In this review, we focus on the compositional changes in the gut microbiome and its related metabolites in various CVDs. Moreover, the potential treatment and preventive strategies targeting the gut microbiome and its metabolites are discussed.
